Geoff MacKay

President & CEO

Geoff is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Geoff is dedicated to applying innovation to reshape and improve the quality of healthcare.

Geoff MacKay

Kim Warren, PhD

Head of Operations

Kim is an experienced scientist with entrepreneurial and business management experience in cell therapy. She spent the last 10 years at Lonza, developing a services business, including tissue acquisition, process development, bioassays and related services to support GMP manufacturing of cellular therapeutics. Kim also headed R&D at Cambrex, developing cell-based research products. She founded and ran Poietic Technologies, acquired by Cambrex in 1999. She has also held research positions in pharma (Otsuka) and biotech (Cetus). Kim has a Ph.D. in Comparative Physiology from University of Maryland and postdoctoral training in Immunology at USUHS, Bethesda MD.


Chris Mason, MD, PhD, FRCS

Chief Science Officer

Chris is a clinician-scientist with over 25 years of cell and gene therapy experience including Full Professor of Cell & Gene Therapy at University College London. He has a multidisciplinary track record spanning R&D, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and commercialization. Chris was instrumental in the founding of the Alliance for Regenerative Medicine, UK-Israel Science Council and the London Regenerative Medicine Network. Current SAB appointments include; public and private companies, the UK Cell & Gene Therapy Catapult, and the Canadian Centre for the Commercialization of Regenerative Medicine. Chris is Senior Editor of the journals; ‘Cell and Gene Therapy Insights’ and ‘Regenerative Medicine’.
Christopher Paige

Deanna Petersen, MBA

Chief Business Officer

Deanna is a broadly skilled senior executive with leadership experience in global business development and strategic planning. Deanna previously was the head of business development for Shire’s rare disease business where she and her team identified and evaluated new business opportunities, and negotiated and executed more than 40 transactions in 5 years (public and private M&A, licenses and other partnerships), including a $4.2 billion dollar acquisition of ViroPharma. Prior to joining Shire, Deanna was Vice President of Business Development at Agenus Inc. and at Coley Pharmaceutical Group. Deanna is on the Board of Directors for Tecogen, Inc. (TGEN) and was previously on Boards for Armagen, American DG Energy (ADGE), the Massachusetts Biotechnology Association, the Boston Chapter of the Healthcare Businesswomen’s Association and for the Boston BioPharma Executive Council.

Deanna Petersen

Nerissa Kreher, MD, MBA

Chief Medical Officer

Nerissa is a pediatric endocrinologist with deep academic, clinical research and biotechnology industry experience. She has held leadership roles in both clinical development and medical affairs within private start-up biotechnology and large biotechnology companies focused on rare diseases. Most recently Nerissa was the Global Head of Clinical and Medical Affairs at Zafgen, Inc. Formerly she held roles of increasing responsibility at Shire, Alexion, Enobia Pharma, Genzyme and EMD Serono. Nerissa received a BS from the University of North Carolina, an MD from East Carolina University School of Medicine, an MS in Clinical Research from Indiana University and an Executive MBA from Northeastern University.


Katina Dorton, MBA, JD

Chief Financial Officer

Katina is an experienced financial executive with more than 20 years of investment banking experience advising corporate clients and their Boards of Directors on capital markets, fundraising, mergers and acquisitions and other strategic transactions. She is an experienced biotech CFO and strategic advisor to numerous companies in life sciences. Prior to AVROBIO, Katina served as CFO to Immatics, an immuno-oncology company based in the US and Germany. 

She is a former Managing Director of Investment Banking at Morgan Stanley in New York and Frankfurt Germany, serving 12 years at the firm. She later was Managing Director, Life Sciences, at Needham & Co. Prior to her investment banking career Katina practiced law in mergers and acquisitions at Sullivan & Cromwell. Katina currently is on the Board of Directors of US Ecology, a NASDAQ listed company where she serves as Lead Director.

Katina holds BA in Economics from Duke University, an MBA from George Washington University and a JD from the University of Virginia.

Katina Dorton

Kathryn McNaughton, PhD

SVP, Portfolio & Program Management

Kathryn has 20 years of experience in the biotech industry encompassing R&D, Program Management and assessment of business development opportunities. She brings to AVROBIO deep expertise in global program leadership and orphan drug development, extending from the preclinical stage through commercialization. Kathryn was previously Vice President, R&D Pipeline Program Management at Synageva, and held roles of increasing responsibility at Shire and Praecis Pharmaceuticals. Kathryn earned a PhD in Chemistry from Princeton University and a BS in Chemistry from Monmouth University